ATXN7 (Ataxin-7)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATXN7 — Ataxin-7</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATXN7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATXN7 — Ataxin-7</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=ATXN7" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Overview
ATXN7 encodes ataxin-7, a nuclear protein that serves as a structural and functional subunit of SAGA-family transcriptional coactivator complexes. The strongest disease link is to [Spinocerebellar Ataxia Type 7](/diseases/spinocerebellar-ataxia-type-7) (SCA7), an autosomal-dominant polyglutamine (polyQ) disorder caused by CAG-repeat expansion in the coding region of the gene.[@david1997][@helmlinger2004] Clinically, SCA7 is notable because neurodegeneration in cerebellar and brainstem systems is paired with progressive retinal degeneration and visual loss.[@ncbi]
Ataxin-7 is biologically important beyond monogenic ataxia because it is embedded in transcriptional and chromatin-regulatory machinery that intersects with pathways broadly relevant to neurodegeneration: proteostasis stress, transcriptional vulnerability, mitochondrial dysfunction, and selective neuronal susceptibility.[@helmlinger2004][@palhan2005]
...ATXN7 (Ataxin-7)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATXN7 — Ataxin-7</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATXN7</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATXN7 — Ataxin-7</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=ATXN7" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Overview
ATXN7 encodes ataxin-7, a nuclear protein that serves as a structural and functional subunit of SAGA-family transcriptional coactivator complexes. The strongest disease link is to [Spinocerebellar Ataxia Type 7](/diseases/spinocerebellar-ataxia-type-7) (SCA7), an autosomal-dominant polyglutamine (polyQ) disorder caused by CAG-repeat expansion in the coding region of the gene.[@david1997][@helmlinger2004] Clinically, SCA7 is notable because neurodegeneration in cerebellar and brainstem systems is paired with progressive retinal degeneration and visual loss.[@ncbi]
Ataxin-7 is biologically important beyond monogenic ataxia because it is embedded in transcriptional and chromatin-regulatory machinery that intersects with pathways broadly relevant to neurodegeneration: proteostasis stress, transcriptional vulnerability, mitochondrial dysfunction, and selective neuronal susceptibility.[@helmlinger2004][@palhan2005]
Gene and Protein Architecture
ATXN7 is located on chromosome 3p and produces multiple transcripts encoding a protein with an N-terminal polyQ tract and domains that mediate assembly into SAGA-family complexes.[@helmlinger2004][@ncbia] In unaffected individuals, the CAG repeat is below the pathogenic range. Expansion above disease threshold produces a longer polyQ region that changes protein conformation, interaction stoichiometry, and aggregation behavior.[@david1997][@ncbi]
Key molecular features
- PolyQ segment: determines disease risk and partially predicts age at onset in SCA7 families.[@david1997][@ncbi]
- SAGA integration role: supports complex integrity and recruitment dynamics at transcriptionally active loci.[@helmlinger2004][@mcmahon2005]
- Nuclear localization: most disease-relevant effects are tied to altered nuclear transcriptional regulation and chromatin state.[@helmlinger2004][@palhan2005]
At the protein level, ATXN7 should be interpreted as both a structural scaffold and a regulator of enzymatic output in coactivator complexes. This dual role helps explain why mutant ataxin-7 can produce large downstream effects from a single-gene lesion.
Physiologic Function in the Nervous System
ATXN7 participates in gene-expression programs required for long-lived [neurons](/entities/neurons) and photoreceptors. Through SAGA-like complexes, it influences histone acetylation balance, promoter accessibility, and stimulus-coupled transcription in post-mitotic cells.[@helmlinger2004][@mcmahon2005]
In neural systems, this function maps to:
- maintenance of transcriptional programs in cerebellar and retinal cells,
- support of stress-response gene expression,
- coordination of chromatin remodeling with ongoing neuronal activity.
Because these cellular populations are metabolically demanding and difficult to replace, even moderate chronic transcriptional distortion can accumulate into progressive dysfunction.[@ncbi][@palhan2005]
Disease Mechanism in SCA7
CAG expansion and toxic gain-of-function
SCA7 is caused by CAG-repeat expansion in ATXN7, leading to expression of polyQ-expanded ataxin-7.[@david1997][@ncbi] Mutant protein can accumulate in intranuclear inclusions, but toxicity is not explained by inclusions alone. A central mechanistic model is transcriptional poisoning: mutant ataxin-7 enters SAGA-family complexes and impairs their histone acetyltransferase-linked output, thereby distorting expression of neuronal and photoreceptor identity programs.[@palhan2005][@mcmahon2005]
Transcriptional and chromatin dysregulation
Work in cellular and mouse systems shows that polyQ-expanded ataxin-7 alters chromatin marks and suppresses critical target genes, including retina-relevant transcriptional networks.[@palhan2005][@tong2022] This provides a mechanistic bridge from molecular lesion (expanded polyQ) to tissue phenotype (progressive visual and cerebellar impairment).
Selective vulnerability
SCA7 highlights selective vulnerability across two highly specialized systems:
- Cerebellar circuitry (ataxia, dysarthria, oculomotor abnormalities)
- Retina/visual pathways (cone-rod degeneration, central vision decline)
Why these tissues are preferentially affected remains an active question, but converging explanations include cell-type-specific transcriptional demand, reduced reserve against proteostasis/chromatin stress, and long-lived post-mitotic biology.[@ncbi][@tong2022]
Clinical Associations
Spinocerebellar Ataxia Type 7 (primary association)
SCA7 displays autosomal-dominant inheritance with anticipation, often most pronounced with paternal transmission due to repeat instability.[@david1997][@ncbi] Core features include:
- progressive gait and limb ataxia,
- dysarthria and impaired eye movements,
- retinal degeneration with visual loss,
- later-stage disability involving swallowing, mobility, and activities of daily living.
Repeat length correlates with earlier onset and more aggressive course at the population level, although individual trajectories vary.[@ncbi]
Broader neurodegeneration relevance
ATXN7 itself is not a common primary risk gene for [Alzheimer's disease](/diseases/alzheimers-disease) or [Parkinson's disease](/diseases/parkinsons-disease), but ATXN7-linked pathways (chromatin regulation, mitochondrial stress, transcriptional fragility) overlap with shared neurodegeneration mechanisms.[@tong2022][@rub2003]
Diagnostics and Biomarker-Relevant Concepts
For suspected SCA7, definitive diagnosis is molecular confirmation of expanded CAG repeats in ATXN7.[@ncbi] Clinical workup typically integrates:
- neurologic examination focused on cerebellar and oculomotor findings,
- ophthalmologic testing (including retinal structure/function assessment),
- family-history mapping for autosomal-dominant transmission patterns.
Potential biomarker directions under study include retinal imaging metrics, quantitative eye-movement phenotypes, and molecular readouts of transcriptional/chromatin stress in accessible biospecimens.[@ncbi][@tong2022][@niewiadomskacimicka2022]
Therapeutic Landscape
There is no approved disease-modifying therapy that reverses SCA7 progression. Current care is multidisciplinary and supportive, including mobility aids, speech/swallow interventions, and vision-focused rehabilitation.[@ncbi]
Emerging disease-modifying strategies
- Allele-selective silencing / CAG-targeting RNA approaches: preclinical studies indicate that reducing mutant expanded transcripts/protein can improve disease phenotypes in model systems.[@kotowskazimmer2024][@scholefield2016]
- Gene-delivery and RNAi platforms: AAV-mediated approaches are being optimized for efficacy and safety in polyQ disorders.[@kotowskazimmer2024]
- Epigenetic/transcriptional rescue concepts: because mutant ataxin-7 perturbs chromatin and coactivator function, targeted restoration of transcriptional programs remains a mechanistically rational strategy.[@palhan2005][@tong2022]
Major translational barriers include brain-wide and retina-relevant delivery, durability of effect, allele specificity, and long-term safety.
Research and Knowledge Gaps
High-priority gaps for ATXN7/SCA7 include:
Cell-type-resolution causality: which neuronal and retinal subpopulations fail first, and why.
Temporal mechanism mapping: how early transcriptional defects convert into irreversible circuit degeneration.
Biomarker qualification: validated markers for progression speed and treatment response.
Therapeutic window definition: identifying stage-specific intervention points for maximal benefit.Bridging these gaps will require integrated human-cohort phenotyping, molecular profiling, and longitudinal interventional studies.
See Also
- [Ataxin-7 Protein](/proteins/ataxin-7)
- [ATXN7 Protein](/proteins/atxn7-protein)
- [Spinocerebellar Ataxia Type 7](/diseases/spinocerebellar-ataxia-type-7)
- [Chromatin Remodeling in Neurodegeneration](/mechanisms/chromatin-remodeling-neurodegeneration)
External Links
- [ATXN7 Gene - NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/8573)
- [Spinocerebellar Ataxia Type 7 - NORD](https://rarediseases.org/rare-diseases/spinocerebellar-ataxia-type-7/)
Brain Atlas Resources
- [Allen Human Brain Atlas: ATXN7](https://human.brain-map.org/microarray/search/show?search_term=ATXN7) — Gene expression data across human brain regions
- [Allen Mouse Brain Atlas: Atxn7](https://mouse.brain-map.org/gene/show?gene_id=104806) — Mouse brain expression patterns
References
[David G, Durr A, Stevanin G, et al, Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion (1997)](https://doi.org/10.1038/ng0997-65)
[Helmlinger D, Hardy S, Sasorith S, et al, Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes (2004)](https://pubmed.ncbi.nlm.nih.gov/15115762/)
NCBI GeneReviews, Spinocerebellar Ataxia Type 7 (n.d.)
[Palhan VB, Chen S, Peng GH, et al, Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration (2005)](https://pubmed.ncbi.nlm.nih.gov/15932940/)
NCBI Gene, ATXN7 ataxin 7 (n.d.)
[McMahon SJ, Pray-Grant MG, Schieltz D, Yates JR 3rd, Grant PA, Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA function in yeast (2005)](https://pubmed.ncbi.nlm.nih.gov/15753125/)
[Tong A, Nguyen L, Tylki-Szymanska A, et al, Polyglutamine-expanded ATXN7 alters a specific epigenetic signature underlying photoreceptor identity gene expression in SCA7 mouse retinopathy (2022)](https://doi.org/10.1186/s12929-022-00892-1)
[Rub U, Schols L, Paulson H, et al, Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia type 7 (2003)](https://pubmed.ncbi.nlm.nih.gov/12473750/)
[Niewiadomska-Cimicka A, Trottier Y, Molecular biomarkers and mechanisms in spinocerebellar ataxia type 7 (2022)](https://doi.org/10.3389/fnins.2022.818757)
[Kotowska-Zimmer A, Mioduszewska B, et al, AAV-mediated CAG-targeting selectively reduces polyglutamine-expanded protein and attenuates disease phenotypes in a spinocerebellar ataxia mouse model (2024)](https://doi.org/10.3390/ijms25084354)
[Scholefield J, Greenberg LJ, Weinberg MS, Arbuthnot PB, Mutant CAG repeats effectively targeted by RNA interference in SCA7 cells (2016)](https://pubmed.ncbi.nlm.nih.gov/28040693/)